SILK — Silk Road Medical Income Statement
0.000.00%
Last trade - 00:00- $1.12bn
- $1.02bn
- $177.13m
- 57
- 17
- 93
- 56
Annual income statement for Silk Road Medical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 63.4 | 75.2 | 101 | 139 | 177 |
| Cost of Revenue | |||||
| Gross Profit | 47.4 | 53.9 | 76 | 101 | 127 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 91.4 | 119 | 149 | 191 | 236 |
| Operating Profit | -28.1 | -44 | -47.5 | -52.2 | -59.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -52.4 | -47.4 | -49.8 | -55 | -55.7 |
| Net Income After Taxes | -52.4 | -47.4 | -49.8 | -55 | -55.7 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -52.4 | -47.4 | -49.8 | -55 | -55.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -52.4 | -47.4 | -49.8 | -55 | -55.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.28 | -1.4 | -1.44 | -1.53 | -1.44 |
| Dividends per Share |